血清EphA5基因启动子甲基化在前列腺癌中的诊断价值分析  

Diagnostic value analysis of serum EphA5 gene promoter methylation in prostate cancer

作　　者：陈文柏 侯先存 李世宝 CHEN Wenbai;HOU Xiancun;LI Shibao(Department of Nuclear Medicine,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu;Medical Technology School of Xuzhou Medical University,Xuzhou 221000,Jiangsu,China)

机构地区：[1]徐州医科大学附属医院核医学科,江苏徐州221000 [2]徐州医科大学医学技术学院,江苏徐州221000

出　　处：《临床检验杂志》2024年第11期855-859,共5页Chinese Journal of Clinical Laboratory Science

基　　金：徐州医科大学创新创业基金(XR224104014)。

摘　　要：目的探讨血清EphA5基因启动子甲基化在前列腺癌(PCa)中的诊断价值。方法选取2022年6月至2023年6月徐州医科大学附属医院收治的PCa患者71例作为PCa组,以同期49例良性前列腺增生(BPH)患者和20例体检健康者作为对照组。采用甲基化特异性聚合酶链式反应(MSP)技术对所有研究对象血清样本进行EphA5基因启动子甲基化分析。采用卡方检验评估EphA5基因启动子甲基化与PCa患者临床病理参数之间的关系;绘制ROC曲线并分析EphA5基因启动子甲基化和前列腺抗原(PSA)水平单独及二者联合检测对PCa的诊断价值。结果MSP检测结果显示,PCa患者血清EphA5基因启动子甲基化率为84.5%(60/71),而BPH患者和体检健康者分别为24.49%(12/49)和15%(3/20),PCa患者EphA5基因启动子甲基化率显著高于BPH患者(P<0.05)和体检健康者(P<0.05);PCa患者血清EphA5基因启动子甲基化率与TNM分期(P<0.05)和Gleason评分(P<0.05)相关;PSA与EphA5基因启动子甲基化单独诊断PCa的ROC曲线下面积(AUC ROC)分别为0.868(95%CI:0.810~0.925)、0.800(95%CI:0.723~0.878),而二者联合检测诊断PCa的AUC ROC可提升至0.901(95%CI:0.853~0.950),其诊断效能优于各指标单项检测。结论PCa患者血清EphA5基因启动子甲基化水平显著高于BPH患者和体检健康者,提示血清EphA5基因启动子甲基化可作为PCa的潜在生物学标志物。Objective To explore the diagnostic value of serum EphA5 gene promoter methylation in prostate cancer(PCa).Methods A total of 71 PCa patients admitted to Affiliated Hospital of Xuzhou Medical University from June 2022 to June 2023 were selected as the study subjects,with 49 patients with benign prostatic hyperplasia(BPH)and 20 healthy individuals during the same period as the control groups.The methylation-specific polymerase chain reaction(MSP)technology was used to detect the methylation status of serum EphA5 gene promoter in all study subjects.The relationships between EphA5 gene promoter methylation and clinic pathological parameters were evaluated by the chi-square test.The receiver operating characteristic(ROC)curve was drawn and used to analyze the diagnostic value of combined detection of EphA5 gene promoter methylation and prostate specific antigen(PSA)in PCa.Results The results of MSP showed that the methylation rate(84.5%,60/71)of serum EphA5 gene promoter in PCa patients was significantly higher than those in BPH patients(24.49%,12/49,P<0.05)and healthy controls(15%,3/20,P<0.05).The methylation rate of serum EphA5 gene promoter in PCa patients was correlated with TNM staging(P<0.05)and Gleason score(P<0.05).The areas under the ROC curve(AUC ROC)of PSA and EphA5 gene promoter methylation in the diagnosis of PCa were 0.868(95%CI:0.810-0.925)and 0.800(95%CI:0.723-0.878),respectively.The AUC ROC of the combined detection of PSA and EphA5 gene promoter methylation in the diagnosis of PCa could be raised to 0.901(95%CI:0.853-0.950),and its diagnostic efficiency was better than the single detection of each indicator.Conclusion The methylation level of serum EphA5 gene promoter in PCa patients is significantly higher than those in BPH patients and healthy controls,indicating that serum EphA5 gene promoter methylation may serve as a potential biomarker of PCa.

关 键 词：EphA5基因 DNA甲基化 前列腺癌 

分 类 号：R446[医药卫生—诊断学]